Interplay between non-coding RNA and insulin signaling pathway and its clinical application

LIU Yuhong; ZHANG Fangfang; LIU Jianxing; LIU Yue; YANG Yue; JIN Liang

doi:10.11665/j.issn.1000-5048.20210303

Journal of China Pharmaceutical University > 2021 > 52(3): 279-286. > DOI: 10.11665/j.issn.1000-5048.20210303

LIU Yuhong, ZHANG Fangfang, LIU Jianxing, LIU Yue, YANG Yue, JIN Liang. Interplay between non-coding RNA and insulin signaling pathway and its clinical application[J]. Journal of China Pharmaceutical University, 2021, 52(3): 279-286. DOI: 10.11665/j.issn.1000-5048.20210303

Citation:

PDF (1027 KB)

Interplay between non-coding RNA and insulin signaling pathway and its clinical application

School of Life Sciences and Technology, China Pharmaceutical University, Nanjing 210009, China

Funds: This work was supported by the National Natural Science Foundation of China (No.82070801)

More Information

Received Date: January 21, 2021
Revised Date: May 13, 2021

Graphical Abstract

Abstract

Abstract

Non-coding RNA (ncRNA) is a type of RNA that has no or limited protein-coding ability. It mainly includes microRNA (miRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), transfer RNA (tRNA), PIWI-interacting RNA (piRNA), and small nucleolar RNA (snoRNA).At present, research has found that ncRNA plays a central role in regulating the function of pancreatic β cells, and that defects of insulin signaling is an important cause of diabetes.This article reviews the relationship between ncRNA and insulin signaling pathway in recent years, and discusses the possibility of ncRNA as a potential therapeutic target and clinical diagnostic marker for diabetes, hoping to provide some reference for the treatment and diagnosis of diabetes.
- non-coding RNA,
- insulin signaling pathway,
- diabetes,
- islet β cells

FullText(HTML)

References (47)

References

[1]	. J Clin Oncol，2016，34（35）：4261-4269.
[2]	Roden M，Shulman GI. The integrative biology of type 2 diabetes［J］. Nature，2019，576（7785）：51-60.
[3]	Rines AK，Sharabi K，Tavares CD，et al. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes［J］. Nat Rev Drug Discov，2016，15（11）：786-804.
[4]	Tang NN，Jiang SY，Yang YY，et al. Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus［J］. Cardiovasc Ther，2018，36（4）：e12436.
[5]	Beltrami C，Angelini TG，Emanueli C. Noncoding RNAs in diabetes vascular complications［J］. J Mol Cell Cardiol，2015，89（Pt A）：42-50.
[6]	Min KH，Yang WM，Lee W. Saturated fatty acids-induced miR-424-5p aggravates insulin resistance via targeting insulin receptor in hepatocytes［J］. Biochem Biophys Res Commun，2018，503（3）：1587-1593.
[7]	Wang L，Zhang N，Pan HP，et al. MiR-499-5p contributes to hepatic insulin resistance by suppressing PTEN［J］. Cell Physiol Biochem，2015，36（6）：2357-2365.
[8]	Zhao XM，Mohan R，?zcan S，et al. MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 （MAP4K4） in pancreatic β-cells［J］. J Biol Chem，2012，287（37）：31155-31164.
[9]	Akerman I，Tu ZD，Beucher A，et al. Human pancreatic β cell lncRNAs control cell-specific regulatory networks［J］. Cell Metab，2017，25（2）：400-411.
[10]	Xu HY，Guo S，Li W，et al. The circular RNA Cdr1as，via miR-7 and its targets，regulates insulin transcription and secretion in islet cells［J］. Sci Rep，2015，5：12453.
[11]	Bartel DP. MicroRNAs：genomics，biogenesis，mechanism，and function［J］. Cell，2004，116（2）：281-297.
[12]	Zhang FF，Ma DS，Zhao WL，et al. Obesity-induced overexpression of miR-802 impairs insulin transcription and secretion［J］. Nat Commun，2020，11（1）：1822.
[13]	Feng SD，Yang JH，Yao CH，et al. Potential regulatory mechanisms of lncRNA in diabetes and its complications［J］. Biochem Cell Biol，2017，95（3）：361-367.
[14]	Deveson IW，Hardwick SA，Mercer TR，et al. The dimensions，dynamics，and relevance of the mammalian noncoding transcriptome［J］. Trends Genet，2017，33（7）：464-478.
[15]	Zhang FF，Liu YH，Wang DW，et al. Obesity-induced reduced expression of the lncRNA ROIT impairs insulin transcription by downregulation of Nkx6.1 methylation［J］. Diabetologia，2020，63（4）：811-824.
[16]	Chen LL，Yang L. Regulation of circRNA biogenesis［J］. RNA Biol，2015，12（4）：381-388.
[17]	Meng SJ，Zhou HC，Feng ZY，et al. CircRNA：functions and properties of a novel potential biomarker for cancer［J］. Mol Cancer，2017，16（1）：94.
[18]	Liu YJ，Liu HT，Li Y，et al. Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p/EZH2 axis［J］. Theranostics，2020，10（10）：4705-4719.
[19]	Shan K，Liu C，Liu BH，et al. Circular noncoding RNA HIPK₃ mediates retinal vascular dysfunction in diabetes mellitus［J］. Circulation，2017，136（17）：1629-1642.
[20]	Pan T. Modifications and functional genomics of human transfer RNA［J］. Cell Res，2018，28（4）：395-404.
[21]	Ozata DM，Gainetdinov I，Zoch A，et al. PIWI-interacting RNAs：small RNAs with big functions［J］. Nat Rev Genet，2019，20（2）：89-108.
[22]	Zimta AA，Tigu AB，Braicu C，et al. An emerging class of long non-coding RNA with oncogenic role arises from the snoRNA host genes［J］. Front Oncol，2020，10：389.
[23]	Kulkarni RN，Brüning JC，Winnay JN，et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes［J］. Cell，1999，96（3）：329-339.
[24]	Hubbard SR. The insulin receptor：both a prototypical and atypical receptor tyrosine kinase［J］. Cold Spring Harb Perspect Biol，2013，5（3）：a008946.
[25]	Leto D，Saltiel AR. Regulation of glucose transport by insulin：traffic control of GLUT4［J］. Nat Rev Mol Cell Biol，2012，13（6）：383-396.
[26]	Cartee GD. Roles of TBC1D1 and TBC1D4 in insulin- and exercise-stimulated glucose transport of skeletal muscle［J］. Diabetologia，2015，58（1）：19-30.
[27]	Cervello M，Augello G，Cusimano A，et al. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma［J］. Adv Biol Regul，2017，65：59-76.
[28]	Hermida MA，Dinesh Kumar J，Leslie NR. GSK₃ and its interactions with the PI3K/AKT/mTOR signalling network［J］. Adv Biol Regul，2017，65：5-15.
[29]	Ono K，Igata M，Kondo T，et al. Identification of microRNA that represses IRS-1 expression in liver［J］. PLoS One，2018，13（1）：e0191553.
[30]	Huang F，Chen J，Wang J，et al. Palmitic acid induces MicroRNA-221 expression to decrease glucose uptake in HepG2 cells via the PI3K/AKT/GLUT4 pathway［J］. Biomed Res Int，2019，2019：8171989.
[31]	Zhu H，Shyh-Chang N，Segrè AV，et al. The Lin28/let-7 axis regulates glucose metabolism［J］. Cell，2011，147（1）：81-94.
[32]	Teleman AA，Maitra S，Cohen SM. Drosophila lacking microRNA miR-278 are defective in energy homeostasis［J］. Genes Dev，2006，20（4）：417-422.
[33]	Goyal N，Sivadas A，Shamsudheen KV，et al. RNA sequencing of db/db mice liver identifies lncRNA H19 as a key regulator of gluconeogenesis and hepatic glucose output［J］. Sci Rep，2017，7（1）：8312.
[34]	Gao Y，Wu FJ，Zhou JC，et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells［J］. Nucleic Acids Res，2014，42（22）：13799-13811.
[35]	Degirmenci U，Li J，Lim YC，et al. Silencing an insulin-induced lncRNA，LncASIR，impairs the transcriptional response to insulin signalling in adipocytes［J］. Sci Rep，2019，9（1）：5608.
[36]	Ruan YT，Lin N，Ma Q，et al. Circulating LncRNAs analysis in patients with type 2 diabetes reveals novel genes influencing glucose metabolism and islet β-cell function［J］. Cell Physiol Biochem，2018，46（1）：335-350.
[37]	Cai HY，Jiang ZR，Yang XN，et al. Circular RNA HIPK₃ contributes to hyperglycemia and insulin homeostasis by sponging miR-192-5p and upregulating transcription factor forkhead box O1［J］. Endocr J，2020，67（4）：397-408.
[38]	Stoll L，Sobel J，Rodriguez-Trejo A，et al. Circular RNAs as novel regulators of β-cell functions in normal and disease conditions［J］. Mol Metab，2018，9：69-83.
[39]	Liu YH，Hou JX，Zhang M，et al. Circ-016910 sponges miR-574-5p to regulate cell physiology and milk synthesis via MAPK and PI3K/AKT-mTOR pathways in GMECs［J］. J Cell Physiol，2020，235（5）：4198-4216.
[40]	LoPiccolo J，Blumenthal GM，Bernstein WB，et al. Targeting the PI3K/Akt/mTOR pathway：effective combinations and clinical considerations［J］. Drug Resist Updat，2008，11（1/2）：32-50.
[41]	J?ger S，Wahl S，Kr?ger J，et al. Genetic variants including markers from the exome chip and metabolite traits of type 2 diabetes［J］. Sci Rep，2017，7（1）：6037.
[42]	Wei FY，Suzuki T，Watanabe S，et al. Deficit of tRNA（Lys） modification by Cdkal1 causes the development of type 2 diabetes in mice［J］. J Clin Invest，2011，121（9）：3598-3608.
[43]	Henaoui IS，Jacovetti C，Guerra Mollet I，et al. PIWI-interacting RNAs as novel regulators of pancreatic beta cell function［J］. Diabetologia，2017，60（10）：1977-1986.
[44]	Lee J，Harris AN，Holley CL，et al. Rpl13a small nucleolar RNAs regulate systemic glucose metabolism［J］. J Clin Invest，2016，126（12）：4616-4625.
[45]	LaPierre MP，Stoffel M. MicroRNAs as stress regulators in pancreatic beta cells and diabetes［J］. Mol Metab，2017，6（9）：1010-1023.
[46]	Zhao Z，Li X，Jian D，et al. Hsa_circ_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus［J］. Acta Diabetol，2017，54（3）：237-245.
[47]	Sharma S，Mathew AB，Chugh J. miRNAs：nanomachines that micromanage the pathophysiology of diabetes mellitus［J］. Adv Clin Chem，2017，82：199-264.

Cited By

Cited by

Periodical cited type(1)

秦怡梦，刘岩，金亮，张方方. circRNA:一种调控糖尿病病理演变的新型分子. 药物生物技术. 2024(04): 444-453 .

Other cited types(2)

Get Citation

PDF

XML

Article views (260) PDF downloads (658) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Interplay between non-coding RNA and insulin signaling pathway and its clinical application

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(2)

Catalog

Export File

Citation

Format

Content